VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | Updates on ropeginterferon in MPNs

Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, shares some updates on the role of ropeginterferon alfa-2b in the treatment of myeloproliferative neoplasms (MPNs), highlighting the efficacy of this agent in comparison to best available therapy (BAT). Prof. Kiladjian further discusses some results from a six-year follow-up study comparing the use of ropeginterferon versus BAT. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Advisory boards for Novartis, Abbvie, BMS, AOP Orphan.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter